Actinium Pharmaceuticals News and Activities
Presence
Headquarters: United States (USA)
Actinium Pharmaceuticals is a company listed under the stock ticker ATNM (US).
Executives
View the org chart displaying its 15 main executives
Most searched biographies at Actinium Pharmaceuticals
- Sandesh Seth, Chairman of the Board and Chief Executive Officer
- David Nicholson, Lead Independent Director
- Ajit Shetty, Director
Popular executive movements at Actinium Pharmaceuticals
- Steffen Heeger has joined the company as Chief Medical Officer (posted on June 1 2026).
- Steve O'Loughlin, Chief Financial Officer, has left the company (posted on March 4 2026).
Create your alert
to follow the executive moves at Actinium Pharmaceuticals.
Pharmaceuticals
Actinium Pharmaceuticals has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).
Popular M&A news in Pharmaceuticals
- Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
- Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
- Apotex has filed its IPO. Its stock ticker will be TSX. (posted on June 2 2026).
Popular contacts in Pharmaceuticals
News
Press releases by Actinium Pharmaceuticals
- Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization :: Actinium Pharmaceuticals, Inc. (ATNM)
- Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting :: Actinium Pharmaceuticals, Inc. (ATNM)
- Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting :: Actinium Pharmaceuticals, In
- Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting :: Actinium Pharmaceuticals, Inc. (ATNM)
- Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting :: Actinium Pharmaceuticals, Inc. (ATNM)
- Press Releases :: Actinium Pharmaceuticals, Inc. (ATNM)
- Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cance
- Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium :: Actinium P
- Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications :: Actinium Pharmaceuticals,
- Actinium Pharmaceuticals, Inc. to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference :: Actinium Pharmaceuticals, Inc. (ATNM)
- View more press releases Close
Social media about Actinium Pharmaceuticals
- Actinium Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
- Actinium Pharmaceuticals on LinkedIn, X (Twitter) & YouTube
